BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/7/2023 6:50:07 AM | Browse: 216 | Download: 675
 |
Received |
|
2023-07-27 03:34 |
|
Peer-Review Started |
|
2023-07-27 03:38 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-09-26 08:56 |
|
Revised |
|
2023-10-07 15:36 |
|
Second Decision |
|
2023-10-19 02:44 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2023-10-23 03:21 |
|
Articles in Press |
|
2023-10-23 03:21 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-10-31 01:25 |
|
Publish the Manuscript Online |
|
2023-11-07 06:50 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Long-term efficacy and predictors of pembrolizumab-based regimens in patients with advanced esophageal cancer in the real world
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hong-Chi Wang, Xiang Huang, Jing Chen, Ye Li, Yang Cong, Bao-Lin Qu, Sheng-Qiang Feng and Fang Liu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Fang Liu, MD, Chief Physician, Department of Radiotherapy, The First Medical Center of Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China. liufangfsq@163.com |
| Key Words |
Esophageal cancer; Pembrolizumab; Radiotherapy; Long-term survival; Chemotherapy; Real-world |
| Core Tip |
Pembrolizumab combined with chemotherapy has been proven effective as first-line therapy in patients with metastatic esophageal cancer. Few trials have assessed the safety and efficacy of this treatment in patients with locally advanced disease. Our study showed that this treatment in patients with locally advanced or metastatic esophageal squamous cell carcinoma resulted in favorable long-term survival and manageable long-term adverse effects. Randomized phase III trials should be carried out for further verification. |
| Publish Date |
2023-11-07 06:50 |
| Citation |
Wang HC, Huang X, Chen J, Li Y, Cong Y, Qu BL, Feng SQ, Liu F. Long-term efficacy and predictors of pembrolizumab-based regimens in patients with advanced esophageal cancer in the real world. World J Gastroenterol 2023; 29(41): 5641-5656 |
| URL |
https://www.wjgnet.com/1007-9327/full/v29/i41/5641.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v29.i41.5641 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
